Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Up Next ? 4Q21: Report complete REVEAL 1 data (ITT, mITT, per protocol)
? 4Q21: Report on pre-treatment biomarker with QIAGEN
? 4Q21: Pursue a registrational Phase 3 clinical trial for HPV-16-/18-associated Vulvar and anal dysplasia, apply for rare and orphan disease designation
? 4Q21: PROVIDE INO-4800 UPDATE ON OMICRON VARIANT
? 4Q21: Report INO-5401 OS24, and immunology data
? 1Q22: Present INO-5401 OS30, and immunology data
? 1Q22: INO-4802 FDA P1/2 IND Approved
? 1Q22: INO-4802 P1/2 Start in India, S. Africa, … with external grants
? 1H22: Report interim efficacy data from Phase 3 INNOVATE trial

A Deep Dive into DNA Damage Repair for GBM
Jeffrey Skolnik
VP Clinical Development Inovio
3rd GBM Drug Development Summit. Boston, 1/20/2022, 8:40A EST

Inovio’s DNA Medicine for the Treatment of Glioblastoma:
• Using novel DNA-encoded medicines to treat human cancers such as GBM
• Generating robust, specific anti-tumor T cells against GBM antigens
• Combining DNA medicine with immune checkpoint inhibitors to build clinical responses
• Inovio’s INO-5401 is a DNA medicine composed of plasmids that encode for the tumor associated antigens human telomerase (hTERT), Wilms tumor-1 (WT-1), and prostate-specific membrane antigen (PSMA); INO-9012 is a synthetic DNA plasmid that encodes for human IL-12 designed to stimulate T cells locally without a systemic effect
• Cemiplimab is a high-affinity, highly potent, human, hinge-stabilized IgG4 monoclonal antibody to the PD-1 receptor

https://glioblastoma-drugdevelopment.com/full-event-guide/

? 1Q22: INO-5151 Phase 2 Prostate Cancer Combination Study
TRIAL: INO-5151 (encoding tumor-associated antigens: PSA, PSMA)
Phase 2 study (PORTER) for
metastatic castration-resistant prostate cancer
Three cohort, 45-patient platform study,
INO-5151 in Cohort C
Cohort C – 15 patients

PICI/CRI will fund & execute the clinical study

INO-5151 (DNA immunotherapy)
CDX-301 (FLT3 ligand) from Celldex Therapeutics
Nivolumab (anti-PD-1) from Bristol-Myers Squibb